Dengue Clinical Trial - A Dengue Sero-prevalence Study in the Metropolitan

Status Recruiting

Clinical Trial Summary

The objective of this observational study of dengue seroprevalence in the metropolitan area of Buenos Aires is to know what percentage of the population has antibodies against dengue in persons 18 years of age or older who are residents of the city of Buenos Aires or its metropolitan area. The main questions to be answered are: - What is the seroprevalence of antibodies against dengue measured by Immunoglobulin G determination by ELISA - Characterize the different dengue serotypes in the affected population. Participants will undergo a small blood draw to determine the presence of Immunoglobulin G antibodies against dengue. - Tests will also be performed to determine infection by flaviviruses other than dengue virus.

Clinical Trial Description

A two-stage stratified design will be used. The primary sampling units will be mostly defined as the census sections of the 2010 National Census of Population, Households and Dwellings. It has 5 strata, constructed through a functional relationship between the income quintiles obtained in the Annual Household Survey (AHS) and the variables that were surveyed in the census. Stratum 1 corresponds to the lowest income population, while stratum 5 corresponds to the highest. The first stage of sampling in this framework will consist of about 100 to 300 primary sampling units, called primary units areas, selected with a probability proportional to size, the measure of size being the total number of dwellings. A sample of 1,487 dwellings is proposed. In each primary unit area, a number of dwellings will be selected to be visited by enumerators, who will make a list of all members residing in the dwelling (regardless of whether they are from the same household) and select a member aged ≥18 years to proceed with the survey. This last selection is a 3rd and final sampling stage that will define the sample of 1487 participants to be tested. The sample size was calculated based on the estimated probability of pre-infection for each of the municipalities and localities participating in the survey. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05919277
Study type	Observational
Source	Fundacion GESICA
Contact	Cristian Biscayart, MD
Phone	541145204002
Email	cristianbiscayart@gmail.com
Status	Recruiting
Phase
Start date	September 11, 2023
Completion date	September 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05321264` - Educational Intervention to Promote Control Behaviors and Prevention of Dengue	N/A
Completed	`NCT01436396` - Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers	Phase 3
Completed	`NCT01391819` - Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children	N/A
Completed	`NCT03641339` - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans	N/A
Completed	`NCT02833584` - Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults	N/A
Completed	`NCT02433652` - Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2	Phase 1
Enrolling by invitation	`NCT02016027` - Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter	Phase 1
Completed	`NCT01477671` - Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children	N/A
Recruiting	`NCT00377754` - Prospective Study of Infant Dengue	N/A
Recruiting	`NCT04582474` - Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso	N/A
Completed	`NCT01983553` - Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Completed	`NCT03803618` - Dengue Effectiveness Study in the Philippines
Active, not recruiting	`NCT05967455` - Homologous Re-infection With Dengue 1 or Dengue 3	Phase 1
Completed	`NCT03631719` - Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Recruiting	`NCT02606019` - The Use of Biomarkers in Predicting Dengue Outcome	N/A
Completed	`NCT02372175` - Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain	Phase 1
Active, not recruiting	`NCT01696422` - Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine	Phase 2
Completed	`NCT00993447` - Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America	Phase 2
Completed	`NCT00375726` - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults	Phase 1
Recruiting	`NCT05153018` - Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms